Literature DB >> 16877277

Genetic polymorphisms of vascular endothelial growth factor and angiopoietin 2 in retinopathy of prematurity.

Ilona Bányász1, Géza Bokodi, Adám Vannay, Beáta Szebeni, András Treszl, Barna Vásárhelyi, Tivadar Tulassay, András Szabó.   

Abstract

Angiogenic factors such as vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2) contribute to development of retinopathy of prematurity (ROP). We aimed to test whether polymorphisms of these factors are associated with ROP. VEGF(-2578) and Ang2(-35) polymorphisms were analyzed with PCR-RFLP method in 200 preterm infants without ROP or with ROP stages 1-5. Our results suggest that there is no association between carrier state of VEGF(-2578) and Ang2(-35) and risk of ROP in preterm infants. The prevalence of VEGF(-2578) "A" allele was lower in preterm boys with severe ROP (stages 4-5) than in those without or with mild ROP (stages 1-3).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16877277     DOI: 10.1080/02713680600801123

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  15 in total

1.  Meta analysis on the relationship between gene polymorphisms of vascular endothelial growth factor and retinal prognosis risk of prematurity.

Authors:  Jun Zhai; Qiu-Hui Jiang; Chun-Xi Liu; Zuo-Rong Tian; Ying-Pu Sun
Journal:  Int J Ophthalmol       Date:  2012-06-18       Impact factor: 1.779

2.  Lack of association of VEGF (-2578 C-->A) and ANG 2 (-35 G-->C) gene polymorphisms with the progression of retinopathy of prematurity.

Authors:  Barkur S Shastry
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-19       Impact factor: 3.117

Review 3.  Retinopathy of prematurity: a review of risk factors and their clinical significance.

Authors:  Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2018-04-19       Impact factor: 6.048

Review 4.  Retinopathy of prematurity: contribution of inflammatory and genetic factors.

Authors:  Mariza Fevereiro-Martins; Hercília Guimarães; Carlos Marques-Neves; Manuel Bicho
Journal:  Mol Cell Biochem       Date:  2022-03-09       Impact factor: 3.396

5.  Association of VEGF gene polymorphisms with advanced retinopathy of prematurity: a meta-analysis.

Authors:  Peihui Liu; De Wu; Weiqin Zhou; Yawen Li; Chaohui Lian; Yueping Yang; Zhichun Feng
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

6.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Authors:  Bryan P Schneider; Molin Wang; Milan Radovich; George W Sledge; Sunil Badve; Ann Thor; David A Flockhart; Bradley Hancock; Nancy Davidson; Julie Gralow; Maura Dickler; Edith A Perez; Melody Cobleigh; Tamara Shenkier; Susan Edgerton; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

Review 7.  [Pathogenesis of retinopathy of prematurity].

Authors:  M Heckmann
Journal:  Ophthalmologe       Date:  2008-12       Impact factor: 1.059

8.  Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy.

Authors:  Shinko Nakamura; Naoko Iwasaki; Hideharu Funatsu; Shigehiko Kitano; Yasuhiko Iwamoto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-16       Impact factor: 3.117

9.  The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity.

Authors:  Przemko Kwinta; Mirosław Bik-Multanowski; Zofia Mitkowska; Tomasz Tomasik; Jacek J Pietrzyk
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-11       Impact factor: 3.117

Review 10.  The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice.

Authors:  Nazimul Hussain; Yashoda Ghanekar; Inderjeet Kaur
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.